ZYME

AI MemoPost-earnings T+3

Zymeworks

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FDA PDUFA decision for zanidatamab • 2026-08-25

Expected move: +32%

Biggest risk

The thesis remains event-driven: FDA approval, the acquisition closing, and clinical updates are not assured. The company did not host a Q2 earnings call, and the packet contains no verified post-print consensus surprise, analyst estimate revision, or target change. Clinical, regulatory, integration, and cash-flow execution risks therefore remain material.

Invalidation

Break below $16 or thesis failure.

What would change my mind?

The bull case rests on the August zanidatamab regulatory decision, potential milestone and royalty expansion, the planned Theravance closing, and additional partnered or wholly owned pipeline catalysts. The Q2 release also described a $322.5 million liquidity position and continued capital returns. [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

$31

p=50%

Bull target

$42

p=25%

Bear target

$16

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

HERIZON-GEA-01 overall-survival update
Partnered pasritamig development update
The bull case rests on the August zanidatamab regulatory decision, potential milestone and royalty expansion, the planned Theravance closing, and additional partnered or wholly owned pipeline catalysts.

BearKey bullets

FDA delay, rejection, or restrictive labeling for zanidatamab could eliminate or defer the potential milestone and royalty uplift.
HERIZON-GEA-01 and other pipeline readouts may disappoint or be delayed.
Low coverage and a loose peer set reduce confidence in valuation triangulation.

WatchKey bullets

FDA PDUFA decision for zanidatamab

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $31 (p=50%)

Bull/Bear spread: +78% / -32%

Vs latest close: Bull +78% · Base +32% · Bear -32%

Scenario probabilities

Bull Target: $42 (p=25%)Base Target: $31 (p=50%)Bear Target: $16 (p=25%)

Commentary

News tone is mixed-positive because the earnings release highlighted multiple second-half catalysts, the Theravance transaction, and capital returns, while external coverage framed the acquisition more cautiously. Social, options, short-interest, and employee data were unavailable. Consensus surprise, post-print target or estimate revisions, and a quantified price reaction were also unavailable; the 2026-08-06 anchor price should not be interpreted as evidence of a favorable earnings reaction.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

HERIZON-GEA-01 overall-survival update
Partnered pasritamig development update

Scenarios

Bull Target (Scenario probability)

$42 / p=25% prob

Base Target (Scenario probability)

$31 / p=50% prob

Bear Target (Scenario probability)

$16 / p=25% prob

Price $24 as of 2026-08-07

Nearest Scenario: Base (∆ 32%)

Targets vs latest close: Bull +78% · Base +32% · Bear -32%

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-25
FDA PDUFA decision for zanidatamab
The August 25, 2026 U.S. PDUFA date for first-line HER2-positive GEA could unlock a $250 million approval milestone and support additional royalty and regulatory cash flows. [#SEC-8K-2026-08-06]
Prob 65.00% • Move 20.00% • Priced-in 55.00%
EVENT2026-11-06
Q2 2026 release confirms royalty base and liquidity
The August 6 release reported $1.8 million of Q2 royalty revenue, $322.5 million of cash, cash equivalents and marketable securities at June 30, and $49.4 million of share repurchases through August 4. Consensus surprise, analyst revisions, and quantified post-print price reaction were unavailable. [#SEC-8K-2026-08-06]
Prob 100.00% • Move 2.00% • Priced-in 80.00%
EVENT2026-11-06
Theravance acquisition closing
Zymeworks expects the proposed Theravance Biopharma acquisition to close in the second half of 2026, subject to regulatory approval and customary closing conditions, adding commercial cash flows to the portfolio. [#SEC-8K-2026-08-06]
Prob 70.00% • Move 10.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

HERIZON-GEA-01 overall-survival update
2027-08-08
Top-line results from the second interim overall-survival analysis for the zanidatamab doublet regimen are expected in Q3 2026, creating a clinically meaningful but binary data point. [#SEC-8K-2026-08-06]
Prob 55% • Move 12% • Priced-in 35%
Partnered pasritamig development update
2027-08-08
Johnson & Johnson expects Phase 1b pasritamig data in the second half of 2026; the Phase 3 program has increased planned enrollment to 1,203 participants and is actively recruiting. [#SEC-8K-2026-08-06]
Prob 50% • Move 8% • Priced-in 25%

Risks

FDA delay, rejection, or restrictive labeling for zanidatamab could eliminate or defer the potential milestone and royalty uplift.
HERIZON-GEA-01 and other pipeline readouts may disappoint or be delayed.
Low coverage and a loose peer set reduce confidence in valuation triangulation.
The Q2 packet does not provide a verified revenue or EPS consensus comparison, post-print analyst revision signal, or quantified market reaction.
The Theravance transaction remains subject to regulatory approval and customary closing conditions, with integration and financing execution risk.

Peers

Symbol	Summary
AAPG	Similar-sector and similar-market-cap screening candidate, but the packet provides no indication-level evidence establishing it as a clean operating comparable.
IMCR	Similar-sector, similar-scale biopharma candidate; useful for broad sentiment context, but pipeline and commercial comparability remain limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

AAPG

Similar-sector and similar-market-cap screening candidate, but the packet provides no indication-level evidence establishing it as a clean operating comparable.

IMCR

Similar-sector, similar-scale biopharma candidate; useful for broad sentiment context, but pipeline and commercial comparability remain limited.